EFPIA member companies join forces to launch the EFPIA Alzheimer's disease Platform

May 6, 2019

 

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has announced the launch of the EFPIA Alzheimer's disease Platform. The goal of this Platform is "To ensure a brighter today and tomorrow for people with Alzheimer's disease". 

 

To do this, the Platform will co-create solutions with key stakeholders and agree on a common approach to ultimately expedite progress in this challenging area of research where little progress has been made in terms of clinical trials. 

 

The key principles of the Platform are outlined in a paper published by EFPIA titled "Taking Action Together to Ensure a Better Today and Tomorrow for People with Alzheimer's Disease".

 

Biogen and Janssen, two of ADAPTED's EFPIA partners, have joined the Platform and we're thrilled to see a positive and collaborative approach to one of the greatest unmet needs in modern healthcare.

 

Alzheimer's disease affects over 11 million people in Europe, with this figure expected to rise to 14 million by 2030.[1] This places a burden on patients, families and carers, as well as health care systems across Europe. 

 

The ADAPTED consortium is working hard to unravel the complexities of the APOE gene and Alzheimer's disease, and now there is an established Platform of top pharmaceutical companies who will support us in taking our research to those who need it most. This will ensure our research will make a real impact to everyone who is living with or affected by Alzheimer's disease. 

[1] Alzheimer Europe, Cost of illness and burden of dementia in Europe - Prognosis to 2030, www.alzheimer-europe.org/Research/European-Collaboration-on-Dementia/Cost-of-dementia/Prognosis-to-2030  

 

  

Please reload

Other Items
Please reload

©2018 ADAPTED

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreement No 115975. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations